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In Brief Rannals et al. show that TCF4 loss of function alters the intrinsic excitability of prefrontal neurons. This excitability phenotype results from ectopic expression of two peripheral ion channels and can be rescued by acute application of antagonists.
INTRODUCTION
Pitt-Hopkins syndrome (PTHS) and 18q syndrome are rare neurodevelopmental disorders characterized by intellectual disability, failure to acquire language, deficits in motor learning, hyperventilation, epilepsy, autistic behavior, and gastrointestinal abnormalities (Whalen et al., 2012; Forrest et al., 2012; Sweatt, 2013; Soileau et al., 2015) . PTHS is caused by a variety of mutations of TCF4 (ITF2, SEF2, E2-2), each of which results in TCF4 protein deficiency (Brockschmidt et al., 2011; Zweier et al., 2008; Amiel et al., 2007; Sepp et al., 2012) . In addition, SNPs in a genomic locus containing TCF4 were among the first to reach genome-wide significance in clinical genome-wide association studies (GWAS) for schizophrenia (Schizophrenia Psychiatric Genome-Wide Association Study Consortium, 2011) and are strongly significant in the most recent GWAS (p = 9.09 3 10
À13
; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) . These neuropsychiatric disorders are each characterized by prominent cognitive deficits, which suggest not only genetic overlap between these disorders but a potentially overlapping pathophysiology.
TCF4 is a basic helix-loop-helix (bHLH) transcription factor (TF) that forms homo-or heterodimers with itself or other bHLH TFs (Henthorn et al., 1990; Corneliussen et al., 1991) . Dimerization allows for recognition of E-box binding sites (motif: CANNTG), and direct DNA binding can result in either repression or activation of transcription depending on the protein complex bound to TCF4 (Massari and Murre, 2000) . TCF4 is highly expressed throughout the CNS during human development (de Pontual et al., 2009 ), but regulation of expression and splicing is complex, as multiple alternative transcripts containing different 5 0 exons and internal splicing have been identified (Sepp et al., 2011) . Limited understanding also exists for the genes regulated downstream of TCF4 and this is complicated by the limited specificity of the E-box sequence as well as context-dependent regulation due to heterodimerization, developmental expression, and cell-type specificity (Guillemot, 2007; Powell and Jarman, 2008) .
To unravel the biology of TCF4 and to gain insight into the pathophysiology resulting from TCF4 haploinsufficiency, we developed an in vivo cell-autonomous model of PTHS, using in utero electroporation (IUE) to knockdown the expression of Tcf4 beginning just prior to neurogenesis in the developing rat prefrontal neocortex. We report here that this genetic manipulation produces intrinsic excitability defects that result from de-repression of the expression of specific ion channel genes that are known to regulate the frequency of action potential (AP) spiking. In addition, these excitability phenotypes were replicated in a mouse model of PTHS. We propose that these intrinsic excitability phenotypes may underlie some aspects of pathophysiology observed in PTHS and schizophrenia and identify potential ion channel therapeutic targets.
RESULTS

The Developmental Expression Pattern of TCF4 across the Lifespan Is Similar between Humans and Rodents
We sought to more precisely characterize the developmental expression patterns of TCF4 in both rat and human to determine critical periods of expression. We observed analogous expression trajectories in both human and rat suggesting developmental regulation of TCF4 may be similar between species. TCF4 mRNA expression peaks in late prenatal life, corresponding to the third trimester of fetal life in humans and postnatal day 1 (P1) in rat, and declines during early childhood before leveling off into adulthood ( Figure 1A ). The rapid rise in TCF4 transcripts during corticogenesis likely implicates a critical time period for TCF4 biology.
Validation of shRNA Constructs to Create a CellAutonomous Model of TCF4 Haploinsufficiency
To gain insight into the function of TCF4 during this prenatal peak in expression and to create a cellular model of PTHS, we designed and validated two shRNA constructs to specifically knockdown Tcf4 in utero at embryonic day 16 (E16) just prior to its rise in late prenatal life. Each shRNA construct targets a unique region of the rat Tcf4 transcript, shTCF4 targets a common 3 0 exon found in all known Tcf4 isoforms, and shTCF4_2 targets a common 3 0 UTR. Both shRNA constructs were validated in vitro and showed consistent knockdown of endogenous Tcf4 mRNA (p < 0.002) and TCF4 protein (p < 0.0001) in transfected rat neuroblastoma cells compared to a control shRNA (shCon) that does not target any known rat sequence but is processed by the cell into an interfering RNA ( Figures 1B-1D) .
Our electroporation targeted the medial prefrontal cortex (mPFC), which is the generally accepted rodent homolog of human prefrontal association cortex, an important brain region associated with cognitive deficits in psychiatric disorders (Goldberg and Weinberger, 1988; Goldman-Rakic, 1994 , 1995 . An example image of our mPFC electroporation is shown in Figure S1 . TCF4 knockdown by shTCF4 did not produce any gross morphological defects in neuronal migration or morphology ( Figure S1 ).
TCF4 Regulates the Intrinsic Excitability of Prefrontal Cortical Neurons
To determine whether in utero suppression of TCF4 negatively impacts the physiology of cortical neurons, we assayed intrinsic excitability by performing whole-cell recordings from IUE-transfected neurons and measured the frequency of AP spiking elicited by a series of depolarizing current pulses. TCF4 knockdown produced a severe and consistent reduction of AP output frequency compared to shCon cells (Figures 2A and 2B ; p < 0.0001). The maximum frequency of spikes elicited by any size and an equal amount of cell lysate sample from each condition was subjected to western blot analysis for endogenous TCF4 protein (shTCF4 = 1.9% ± 2.0% of control, n = 4, Bonferroni p < 0.0001; shTCF4_2 = 36.4% ± 4.3% of control, n = 4, Bonferroni p < 0.0001). (D) Rat neuroblastoma cells were transfected with shRNA constructs and subjected to qRT-PCR for Tcf4 transcript (shTCF4 = 0.55-± 0.15-fold change from control, n = 4, Bonferroni p = 0.0065; shTCF4_2 0.47-± 0.11-fold change from control, n = 4, Bonferroni p = 0.0017). Values are presented as mean ± SEM (A and D) or Tukey boxplots (C) and statistical significance via Bonferroni post hoc analysis (**p<0.01, #p<0.0001).
current pulse for each cell was also significantly reduced by both TCF4 shRNA constructs ( Figure 2C ; p < 0.0001). We obtained several other intrinsic excitability measurements from these recordings (Table S1 ) and the only consistent effect observed between both shTCF4 and shTCF4_2 was an increase in the resting membrane potential (RMP; p < 0.0001) and the peak amplitude of the AP (p < 0.0003). Consistent with these and other intrinsic excitability deficits, we also observed an increased variance of AP amplitudes in response to simulated trains of synaptic inputs ( Figure S2 ).
Targeted knockdown of gene expression by RNA interference is potentially complicated by off-target knockdown due to sequence-dependent and sequence-independent effects (Alvarez et al., 2006; Baek et al., 2014) . In addition to showing phenotypic overlap using two independent TCF4 shRNA constructs, we controlled for sequence-dependent effects by performing rescue experiments. Co-expression of human TCF4B + shTCF4 resulted in a complete rescue of AP output (Figures 2B and 2C) . To control for sequence-independent offtargets effects, we designed a CRISPR-Cas9 construct to mutate/knockout Tcf4 (crTCF4). In vitro validation of crTCF4 in transfected rat neuroblastoma cells showed it was effective at making targeted mutations in the Tcf4 locus as measured by the SURVEYOR nuclease assay ( Figure S3A ) and was effective at knockdown of endogenous TCF4 ( Figure S3C ). crTCF4 was delivered via IUE and produced a significant reduction in the frequency neuronal spiking compared to crEmpty cells (Figures 2D and 2E; p < 0.0001) . Maximum spiking frequency analysis showed that crTCF4 cells had significantly reduced AP output compared to crEmpty cells (p = 0.0016). Phenocopy by crTCF4 indicates that the altered intrinsic excitability associated with shRNA suppression of TCF4 is primarily due to disruption of TCF4 signaling and not the result of off-target effects.
TCF4 Regulates the Afterhyperpolarization in mPFC Neurons
To more fully characterize the molecular mechanism responsible for the reduction of AP output in shTCF4 neurons, we measured the afterhyperpolarization (AHP) that regulates neuronal spike frequency. Calcium-activated potassium channels (C) Group data depicting the maximum AP frequency obtained from each neuron from all conditions. Post hoc comparisons of the maximum AP frequency indicated that shTCF4 (15.79 ± 1.8 Hz, n = 30; Bonferroni p < 0.0001) and shTCF4_2 (20.77 ± 1.5 Hz, n = 41; Bonferroni p = 0.032) were significantly reduced compared to shCon (25.51 ± 1.04 Hz, n = 35). (D and E) In utero knockout of TCF4 by CRISPR-Cas9-mediated mutation prevents neurons from displaying repetitive spiking. (D) Sample current-clamp traces recorded from EGFP+ neurons expressing crEmpty or crTCF4 in response to 600 ms current injections (+300 and À50 pA). (E) Summary data of the frequency of APs generated in response to current injections. crTCF4 produced a significant reduction in the frequency neuronal spiking compared to crEmpty cells. Post hoc analysis indicated that crTCF4 cells (n = 20) between 150 and 500 pA produced significantly fewer spikes than crEmpty cells (n = 17). (F) Group data depicting the maximum AP frequency obtained from each neuron in each condition. The maximum spiking frequency analysis showed that crTCF4 cells (16.89 ± 1.54 Hz, n = 20; unpaired t test p = 0.0016) were significantly reduced compared to crEmpty cells (24.90 ± 1.78 Hz, n = 17). Values are presented as mean ± SEM (B and E) or Tukey boxplots (C and F) and statistical significance via Bonferroni post hoc analysis (B, C, and E) or unpaired t test (F) (*p < 0.05, **p < 0.01, &p < 0.001, #p < 0.0001).
hyperpolarize the membrane, making it less likely that neurons will reach threshold and fire subsequent APs (Hille, 2001; Sah and Faber, 2002; Vogalis et al., 2003; Bean, 2007) . Several potassium channel conductances are responsible for producing the AHP and they are characterized by their kinetics such that the AHP consists of a fast (fAHP), medium (mAHP), and slow component (sAHP) (Sah and Faber, 2002) . Because the mAHP and sAHP are inversely correlated with average firing rate and the amplitude of the sAHP depends on the number of spikes (Lorenzon and Foehring, 1995; Abel et al., 2004) , we measured the mAHP and sAHP from traces showing spiking frequencies of 12 ± 1.0 Hz ( Figure 2C ), which corresponds to the median of the maximum spiking for shTCF4 cells.
Both the mAHP (p < 0.0001) and sAHP (p = 0.0003) were significantly larger in shTCF4 cells compared to shCon cells ( Figures  3B and 3C ). We did not find a significant difference in the fAHP between shTCF4 and shCon cells (p = 0.33). In addition, we observed that the mAHP (p = 0.029), but not the sAHP (p = 0.28), was larger in crTCF4 cells compared to crEmpty cells ( Figure S3 ). These results indicate that TCF4 regulates neuronal output spiking through its control of the AHP.
To further validate the role of TCF4 in regulating the AHP and to more precisely pinpoint the underlying conductances responsible for the increase in the AHP, we conducted voltage-clamp experiments to isolate specific calcium-activated potassium channel currents. We observed that shTCF4 neurons displayed significantly larger capacitance-normalized charge transfer compared to shCon neurons (p = 0.008). Progressive pharmacological blockade was then used to isolate specific components of the AHP. The fAHP is primarily produced by the large conductance calcium-activated big potassium channels (BK) and is blocked by the nonselective antagonist TEA (1 mM). We observed that the AHP current from TCF4 knockdown neurons remained significantly increased in the presence of TEA (Figures 3E and 3G; p = 0.0096). The mAHP is produced by the small conductance calcium-activated potassium channels (SK) and is selectively sensitive to apamin (Sah and Faber, 2002 ). Application of apamin (100 nM) blocked the mAHP in both conditions, and the remaining sAHP current was still significantly increased in shTCF4 cells compared to shCon cells (Figures 3F and 3G; p = 0.013) . Because apamin is highly selective for SK channels, we subtracted the AHP current traces generated before and after its application to isolate the apamin-sensitive component ( Figure 3H ). This subtraction did not reveal a significant difference (p = 0.53) in the apamin-sensitive current between our conditions ( Figure 3I ), suggesting that SK channel expression does not appear to be altered by TCF4 knockdown. From these results, the exact identity of the responsible conductance could not be determined; however, these data replicate our current-clamp results ( Figures 3A-3C ) and strengthen the conclusion that TCF4 is regulating neuronal spiking via the AHP.
TCF4 Regulates the Expression of KCNQ1 and SCN10a
While we identified that TCF4 significantly associates with the AHP (Figure 3 ), our voltage-clamp experiments did not identify the exact conductance(s) regulated by TCF4. We therefore used molecular profiling to identify the particular genes responsible for the intrinsic excitability phenotype by adapting translating ribosome affinity purification (TRAP) (Heiman et al., 2008 (Heiman et al., , 2014 for use with IUE, in a novel approach we term ''iTRAP.'' We co-expressed the EGFP-fused ribosomal protein L10a-EGFP with either shTCF4 or shCon and performed affinity purification from IUE-transfected mPFC brains on P21. A major advantage of this technique is that IUE specifically transfects a homogenous population of layer-specific excitatory neurons (Langevin et al., 2007) , and we validated that iTRAP enriches for excitatory neurons by comparing the expression of celltype-specific markers between our EGFP affinity-bound RNA fraction and unbound RNA fraction. Consistent with excitatory neuronal enrichment, we observed an approximate 2-fold decrease in the expression of Gad1 (p = 0.007), Gfap (p = 0.01), and Olig1 (p = 0.0003) in our EGFP-bound fraction compared to unbound fraction ( Figure 4B ). In addition, we observed a greater than 400-fold increase in the expression of egfp (p = 0.0006). We next compared the ion channel translatome of TCF4 knockdown neurons to shCon neurons using prefabricated 384-well qPCR plates containing the majority of known ion channel genes in the rat genome. This analysis revealed only two ion channel genes, Kcnq1 (Kv7.1; p < 0.005) and Scn10a (Nav1.8; p < 0.01), that were significantly upregulated in shTCF4 neurons compared to shCon neurons. We demonstrated that enrichment via the iTRAP protocol was required because Kcnq1 and Scn10a expression was not significantly different when measured from total RNA from whole frontal cortex homogenates ( Figure S4 ). Remarkably, both of these genes have previously been implicated in regulating spike frequency adaptation (Delmas and Brown, 2005; Blair and Bean, 2003) and thus are strong candidate genes underlying our excitability phenotype.
To determine whether TCF4 directly binds to KCNQ1 and SCN10a, we first analyzed the publicly available ENCODE datasets of TCF4 ChIP-seq performed in human K562 cell line (Consortium, 2012) . After aligning the raw reads to the genome and calling peaks (Ji et al., 2008) , we identified two genome-wide significant (at FDR < 5%) peaks in both of these genes. In KCNQ1, both peaks (chr11:2799700-2800099, FDR = 0.005 and chr11:2760400-2760749, FDR = 0.013) were located in intronic sequence, and both contained multiple canonical E-box binding motifs (CANNTG, first peak: 2, second peak: 9). Similarly, in SCN10a, both peaks (chr3:38765550-38766049, FDR < 1 3 10 À4 and chr3:38767100-38767499, FDR < 1 3 10 À4 )
were located in intronic sequence and both contained multiple canonical E-box binding motifs (CANNTG, first peak: 2, second peak: 6). We then performed ChIP-seq of endogenous TCF4 in rat neuroprogenitor cell cultures to confirm these results in our rodent system. We again found multiple significant peaks in both genes (compared to an untreated input sample, see Experimental Procedures), including 11 genome-wide significant peaks in and around (within 20 kb) Kcnq1 and 4 genome-wide significant peaks in and around Scn10a (Table S2) . These results in both human and rat indicate TCF4 directly binds to genomic regions within KCNQ1 and SCN10a and suggests TCF4 could directly regulate the expression of these genes.
Molecular and Pharmacological Validation of SCN10a and KCNQ1 as Candidate Genes Associated with TCF4-Dependent Regulation of Intrinsic Excitability
To validate our iTRAP experiment and to further understand the underlying molecular mechanism responsible for the TCF4-dependent effects on intrinsic excitability, we utilized pharmacological and molecular methods to both rescue and phenocopy our shTCF4 phenotypes. UCL2077 and JNJ303 are two competitive antagonists with selectivity for KCNQ potassium channels (Towart et al., 2009; Soh and Tzingounis, 2010) . UCL2077 is a KCNQ subtype-selective blocker that strongly inhibits KCNQ1 and KCNQ2 (Soh and Tzingounis, 2010) , whereas JNJ303 is a potent KCNQ1 antagonist (IC 50 = 64 nM) with unknown subtype selectivity (Towart et al., 2009 ). We tested these antagonists using a within-neuron design and observed that both UCL2077 (p = 0.0002; CrTCF4 p = 0.045, Figure S5 ) and JNJ303 (p = 0.0084) were effective at increasing the spiking frequency in shTCF4 neurons ( Figure 5 ). Importantly, neither UCL2077 (p = 0.35) nor JNJ303 (p = 0.11) had an effect on spiking in shCon cells (Figures 5C and 5F; UCL2077 on crEmpty cells p = 0.99, Figure S5C ). In addition, we measured the amplitudes of the mAHP and sAHP before and after application of UCL2077 or JNJ303. Consistent with increased Kcnq1 expression contributing to the AHP amplitude, UCL2077 and JNJ303 were both effective at reducing both the mAHP (UCL2077 p = 0.003; JNJ303 p = 0.044) and sAHP (UCL2077 p = 0.039, JNJ303 p = 0.041) amplitudes in shTCF4 neurons. Notably and coherent with spike frequency data, neither UCL2077 nor JNJ303 had any consistent effect on the amplitudes of the mAHP (UCL2077 p = 0.89; JNJ303 p = 0.40) or sAHP (UCL2077 p = 0.91, JNJ303 p = 0.20) in shCon cells. These pharmacological results suggest that reduced firing frequencies observed in shTCF4 neurons are associated with enhanced KCNQ1 expression that result in a subsequent increase in the amplitude of the AHP.
To validate SCN10a, we first overexpressed a recombinant Scn10a construct to phenocopy TCF4 knockdown. We used IUE to co-transfect SCN10a + shCon and, remarkably, this manipulation resulted in a consistent phenocopy of the intrinsic excitability deficits observed with TCF4 suppression. SCN10a + shCon expression produced a significant decrease in spiking frequency compared to shCon cells ( Figure 6B ; p < 0.0001) and also depolarized the RMP (p < 0.0001) to a similar magnitude observed in TCF4 knockdown cells ( Figure 6C ). Bath application of a selective SCN10a antagonist (A-803467; 200 nM) was effective at increasing firing frequency in shTCF4 cells ( Figure 6D ; p < 0.05) and crTCF4 cells ( Figure S5 ; p = 0.039). Importantly, A-803467 had no effect on firing frequency in shCon cells (p = 0.14) or crEmpty cells (p = 0.15; Figure S5D ). The selective effect of A-803467 only on shTCF4 and crTCF4 cells suggests that SCN10a is overexpressed in these neurons.
To further rule out the potential of nonspecific pharmacology of antagonists to both KCNQ1 and SCN10a, we designed and validated CRISPR-Cas9 constructs that target both Kcnq1 and Scn10a ( Figure 6F ). Co-expression of crKCNQ1, crSCN10a, and shTCF4 resulted in complete rescue of AP spike output (Figure 6G ; p < 0.0001). Together, these results robustly validate our iTRAP method and suggest that under normal conditions, TCF4 represses the expression of KCNQ1 and SCN10a in layer 2/3 neurons of the rat prefrontal cortex.
Phenocopy in a Mouse Model of PTHS
We next sought to validate the intrinsic excitability phenotypes that we have observed in our cell-autonomous model of PTHS in a mouse model in which we measured input-output curves from mPFC neurons (Sweatt, 2013; Grubi si c et al., 2015) . This mouse model was created by insertion of a neo cassette into EcoRV sites within the bHLH domain of Tcf4 ( Figure S7 ) and 0 1 2 3 4 5 shTCF4 vs shCon Fold Change
L10a-EGFP (layer 2/3 pyramidal cells) was originally believed to result in a constitutive deletion of one allele of the Tcf4 gene, thus modeling germline TCF4 haploinsufficiency (Zhuang et al., 1996) . To validate this model at the protein level, we performed western blots from embryonic day 18 (E18) embryos and observed a truncated protein band that was dependent on genotype ( Figure 7A ), suggesting the presence of a potentially dominant-negative protein (Sepp et al. 2012 ). Remarkably, whole-cell recordings in layer 2/3 neurons from Tcf4 +/tr brain slices produced a severe and consistent reduction of spike output (Figures 7B and 7C ; p < 0.0001) and the maximum number of spikes elicited by any size current pulse for each cell was also significantly reduced compared to recordings from Tcf4 +/+ littermates (Tcf4 +/tr 24.4 ± 1.1 Hz, n = 27 versus Tcf4 +/+ 29.9 ± 1.1 Hz, n = 24, p < 0.007). Tcf4 +/tr cells also (B) Summary data of the effect of UCL2077 application on the frequency of APs in shTCF4 cells generated in response to current injections (n = 17). Post hoc analysis indicates UCL2077 significantly increased firing frequency for current pulses between 250 and 500 pA. (B1 and B2) Before and after plots depicting the effect of UCL2077 application on the amplitudes of the mAHP (before À4.43 ± 0.55 mV versus after À3.736 ± 0.49 mV, n = 19, paired t test p = 0.003) and sAHP (before À2.88 ± 0.42 mV versus after À2.53 ± 0.38 mV, n = 19, paired t test p < 0.05) on shTCF4 cells. (C) Summary data of the effect of UCL2077 application on the frequency of APs in shCon cells generated in response to increasing current injections (n = 8). (C1 and C2) Before and after plots depicting the effect of UCL2077 application on the amplitudes of the mAHP (before À3.78 ± 0.66 mV versus after À4.01 ± 0.66 mV, n = 9, paired t test p = 0.20) and sAHP (before À2.60 ± 0.42 mV versus after À2.69 ± 0.48 mV, n = 9, paired t test p = 0.68) on shCon cells.
(D) Representative current-clamp traces from an shTCF4 cell showing the effect of JNJ303 (1 mM) on the frequency of AP spiking. (E) Summary data of the effect of JNJ303 application on the frequency of APs in shTCF4 cells generated in response to current injections (n = 8). Post hoc analysis indicates JNJ303 significantly increased firing frequency for current pulses between 250 and 500 pA. (E1 and E2) Before and after plots depicting the effect of JNJ303 application on the amplitudes of the mAHP (before À3.52 ± 0.58 mV versus after À2.77 ± 0.36 mV, n = 8, paired t test p < 0.044 and sAHP (before À2.31 ± 0.46 mV versus after À1.71 ± 0.33 mV, n = 8, paired t test p = 0.041) on shTCF4 cells. (F) Summary data of the effect of JNJ303 application on the frequency of APs in shCon cells generated in response to increasing current injections (n = 8). (F1 and F2) Before and after plots depicting the effect of JNJ303 application on the amplitudes of the mAHP (before À5.93 ± 0.58 mV versus À5.61 ± 0.74 mV, n = 9, paired t test p = 0.91) and sAHP (before À4.67 ± 0.48 mV versus after À4.22 ± 0.57, n = 9, paired t test p = 0.20) on shCon cells. Values are presented as mean ± SEM and statistical significance via Bonferroni post hoc analysis (B, C, and E) or paired t test (*p < 0.05, **p < 0.01, #p < 0.0001).
displayed a significantly depolarized RMP compared to Tcf4
littermates ( Figure 7D ; p = 0.0037). In contrast to our cell-autonomous model, both the mAHP (Tcf4 +/tr À4.9 ± 0.5 mV, n = 46 versus Tcf4 +/+ À5.6 ± 0.5 mV, n = 35, p < 0.31) and sAHP (Tcf4 +/tr À3.4 ± 0.4 mV, n = 46 versus Tcf4 +/+ À4.4 ± 0.4mV, n = 35, p < 0.15) amplitudes were slightly decreased, but not significantly different, between Tcf4 +/tr and Tcf4 +/+ recordings.
The remarkable phenotypic overlap between our two model systems suggests deficits in AP output may represent a true pathophysiological state in PTHS; however, the subtle differences between our model systems may indicate different underlying mechanisms may exist. If the truncated TCF4 protein that is expressed in this mouse model is capable of binding to wild-type TCF4 protein in a dominant-negative fashion, this could likely lead to different cellular and molecular mechanisms being responsible for the excitability phenotypes observed in our two PTHS models. Therefore, we measured total RNA from frontal cortex homogenates from Tcf4 +/tr and Tcf4 +/+ littermates and consistent with our electrophysiological results, we observed a significant 246% ± 0.5% increase in Scn10a (p = 0.027) expression but only a 32% ± 0.2% decrease in Kcnq1 (p = 0.015) expression ( Figure 7G ). To determine whether these expression differences translate to physiological differences, we tested the effects of SCN10a and KCNQ1 antagonists on AP output. The SCN10a antagonist A-803467 was effective at rescuing AP output in TCF4 +/tr cells but the KCNQ1 antagonist UCL2077 had no effect ( Figure 7I ; Figure S6 ). These results confirm a role of SCN10a in the intrinsic excitability phenotype in this PTHS mouse model.
DISCUSSION
We have performed a series of experiments to illuminate the role of TCF4 as a susceptibility factor in neurodevelopmental psychiatric disorders, specifically describing the biological function and the pathophysiological consequence of TCF4 haploinsufficiency and dominant-negative isoforms associated with PTHS. (G) Summary data of the effect of co-expressing shTCF4 + crSCN10a + crKCNQ1 on the frequency of APs generated in response to increasing current injections. Post hoc analysis indicates that CRISPR-Cas9-mediated mutation of Scn10a and Kcnq1 significantly rescues AP firing for current pulses between 300 pA and 500 pA compared to co-expression of shTCF4 + crEmpty. Values are presented as mean ± SEM (B, D, E, and G) or Tukey boxplots (C) and statistical significance via Bonferroni post hoc analysis (B, C, D, E, and G) (*p < 0.05, **p < 0.01, &p < 0.001, #p < 0.0001).
We developed a novel in vivo cellular model that mimics aspects of TCF4 expression observed in PTHS. We show isomorphic expression trajectories in the human DLPFC and rat cortex across the lifespan, identifying a peak of TCF4 expression during cortical development that subsides during the postnatal period. Based on this early expression pattern, we established a developmental cellular assay by using IUE to knockdown of Tcf4 expression just prior to the peak of Tcf4 expression in the rat. We propose that this creates a cell-autonomous model of PTHS.
Using this approach, we have identified a novel and robust function of TCF4 in the regulation of intrinsic excitability of prefrontal neurons. We show that in utero suppression of TCF4 significantly affects excitability by increasing the magnitude of the AHP and reducing AP output. To identify the molecular mechanisms for these phenotypes, we developed iTRAP, a new molecular profiling technique that provides access to the translatome of IUE-transfected cortical neurons. In the past, experiments using IUE have been hampered by the mosaic expression pattern produced by electroporation and the inability to (H) Representative current-clamp traces from a TCF4 +/tr cell showing UCL2077 has no effect on the frequency of AP spiking.
(I) Summary data of the effect of UCL2077 application on the frequency of APs in TCF4 +/tr cells generated in response to current injections (n = 8). Values are presented as mean ± SEM (C, F, I, and G) or Tukey boxplots (D) and statistical significance via Bonferroni post hoc analysis (C, F, and I) or unpaired t test (G) (*p < 0.05, **p < 0.01, &p < 0.001, #p < 0.0001).
selectively isolate transfected cells for molecular or biochemical profiling. iTRAP overcomes this technical issue and opens the door for future mechanistic studies on the function of genes associated with neuropsychiatric disorders. By comparing the translatome between shTCF4 and shCon neurons with iTRAP, we identified significant upregulation of Kcnq1 and Scn10a translation. Analysis of two independent TCF4 ChIP-seq data (Consortium, 2012) showed direct binding of TCF4 to genomic regions within KCNQ1 and SCN10a, indicating direct regulation of these genes by TCF4. KCNQ1 is a member of the KCNQ gene family, which encodes five voltage-gated, delayed rectifier potassium channels (KCNQ1 to KCNQ5; Kv7.1 to Kv7.5) known to be the molecular components of the M-current (Delmas and Brown, 2005) . Consistent with our results, the KCNQ family appears to contribute to the sAHP (Tzingounis et al., 2007; Tzingounis and Nicoll, 2008; Soh and Tzingounis, 2010) . We show that the KCNQ1 antagonists UCL2077 and JNJ303 were effective at blocking the mAHP and sAHP, and this resulted in rescue of spike frequency in shTCF4 cells. Importantly, this effect was selective to shTCF4 cells and not shCon cells. While KCNQ1 selectivity of UCL2077 is known, the selectivity for KCNQ1 of JNJ303 over other KCNQ subunits is not reported, but our results would indicate that it is similarly selective. It is known that KCNQ channels activate slowly upon depolarization (Jentsch, 2000) , and neuron modeling indicates that the AHP amplitude is increased at depolarized RMPs (Gu et al., 2005) . We observed in the majority of our genetic manipulations that the RMP is depolarized when TCF4 is suppressed (Table S1 ) and this effect may be favorable to enhancing KCNQ1 currents; however, holding shTCF4 cells at more hyperpolarized RMPs had no effect on AP output (ANOVA RMP p = 0.48) or the AHP amplitude (mAHP p = 0.73; sAHP p = 0.87). Together, these results confirm our iTRAP molecular profiling experiments and suggest that TCF4 is regulating the expression of KCNQ1 in L2/3 pyramidal cells.
SCN10a (NaV1.8) is a peripherally expressed, TTX-resistant, voltage-gated sodium channel that shows prominent slow inactivation (Vijayaragavan et al., 2001) shown to be responsible for spike-frequency adaptation in dorsal root ganglion neurons (Blair and Bean, 2003) . We validated TCF4 regulation of SCN10a by showing that SCN10a overexpression resulted in phenocopy of RMP and action potential output. In addition, a specific NaV1.8 antagonist (A-803467) showed selective rescue only in shTCF4 cells. The exact biophysical mechanism responsible for this phenocopy is not known. To our knowledge, wildtype SCN10a is not known to regulate the RMP; however, a SCN10a point mutant (I1706V) found in a patient with idiopathic small-fiber neuropathy led to a depolarized RMP in dorsal root ganglion cells (Huang et al., 2013) . It is reasonable to infer that increasing the expression of a sodium channel would favor a more depolarized RMP. The effect of SCN10a on AP output likely involves slow inactivation of the channel during a train of APs (Blair and Bean, 2003) . It is important to note that TTX-resistant sodium currents are thought to be only expressed in the peripheral nervous system (Baker and Wood, 2001; McCleskey and Gold, 1999) , and to our knowledge this is the first report of a role of expression of Scn10a in the CNS despite suggestions that SCN10a mRNA is present at low levels in the mouse and human neocortex (Lein et al., 2007; Hawrylycz et al., 2012) .
As further validations of the intrinsic excitability phenotypes we found in our cell-autonomous model of PTHS, we observed similar deficits in AP output in a mouse model of PTHS in which one allele of Tcf4 produces a truncated TCF4 protein. This mouse model more closely matches the molecular biology of PTHS (Sweatt, 2013) and therefore may provide more meaningful representation of pathophysiology in PTHS. Homozygous deletion of TCF4 is lethal at birth and defects in progenitor cell migration in the pontine nucleus are reported (Flora et al., 2007) . Heterozygous mice, which model the genetic abnormality of PTHS in humans, exhibit abnormal gut function, the most common non-neurological symptom in PTHS patients (Grubi si c et al., 2015) , and thus substantiates this mouse as a model of at least some fundamental aspects of PTHS.
Although deficits in AP output was a consistent phenotype observed in every experimental approach and between two model systems, we did observe some variability in the data (Table S1). This variability is not unexpected and is likely due to differences in the specific mechanism of action that each molecular approach targets (i.e., at the level of DNA, RNA, or protein), their varying magnitude of effect on TCF4 expression, and the known heterogeneity within pyramidal cells of layer 2/3 (Tyler et al., 2015) . Therefore, we believe this variability is peripheral to the consistently observed result that TCF4 regulates spike frequency through regulation of SCN10a as demonstrated using pharmacological and molecular rescue and phenocopy.
It is also noteworthy that the underlying mechanism was only partially consistent between our rat and mouse models. This mechanistic difference is likely attributable to model construction, as shTCF4 and crTCF4 produce haploinsufficiency, while expression of a truncated TCF4 protein is likely a dominant negative. The divergent expression of Kcnq1, yet similar expression of Scn10a, between these two models indicates that transcriptional control by TCF4 is different depending on the gene being regulated and is consistent with context dependence of bHLH proteins (Powell and Jarman, 2008) . From our data, we would predict that Scn10a and Kcnq1 are differentially regulated by TCF4 through its ability to form homo-or heterodimers and this may explain the varied symptomology observed in the PTHS patient population. The physiological abnormalities that we observe in the cortex of these mice implicate an abnormality of neuronal excitability as a possible mechanism of the cognitive disability also observed in this condition. Moreover, the consistency of the excitability phenotypes between the mouse model and the cell-autonomous model support the conclusion that TCF4 is a regulator of intrinsic neuronal excitability and that Scn10a is at least in part a factor in mediating this effect.
TCF4 is linked to several neuropsychiatric disorders including schizophrenia, PTHS, and 18q deletion syndrome. For schizophrenia, common variants, some within introns of TCF4, have reached genome-wide significance for association with diagnosis (Schizophrenia Psychiatric Genome-Wide Association Study Consortium, 2011) . In addition, several TCF4 SNPs, including some risk SNPs, are associated with SZ endophenotypes including cognition and sensorimotor gating (Zhu et al., 2013; Quednow et al., 2011) . However, the molecular mechanism for these associations is not known, as none of these genetic variants have been shown to be associated with expression differences (Williams et al., 2011) . Given that TCF4 dominant-negative or haploinsufficiency results in PTHS, a syndrome with much more profound neurodevelopmental deficits than those observed in schizophrenia, the mechanism of schizophrenia risk associated with TCF4 is presumably due to less extreme alterations in TCF4 expression at some unknown time point in development. It is also unclear whether the physiological phenotype related to cortical excitability is a feature of the TCF4 risk factor associated with schizophrenia, but studies of cortical physiology in patients with schizophrenia and in their healthy siblings have implicated altered cortical excitability (Callicott, 2003) .
PTHS syndrome is characterized by variable symptomatology presumably because of allelic heterogeneity represented in the deletions/mutations, producing both haploinsufficiency and/or dominant-negative effects (Sepp et al., 2012) . We suggest this expression deficiency leads to intrinsic excitability defects in part due to altered expression (i.e., derepression) of KCNQ1 and SCN10a. The pathological expression of these peripheral ion channels in the CNS may create a unique opportunity to target these channels with therapeutic agents without producing unwanted off-target effects on normal neuronal physiology, and we speculate that targeting these ion channels may ameliorate cognitive deficits observed in PTHS and potentially schizophrenia.
EXPERIMENTAL PROCEDURES Animals and In Utero Electroporation
Pregnant Wistar rats were obtained from Charles River Laboratories and maintained by SoBran on a 12 hr light cycle and fed ad libitum. In utero electroporation was performed as previously described (Maher and Loturco, 2012a; Chen et al., 2014) . Electroporation was performed on embryonic day 16 (E16) and gestation age was confirmed during surgery. All plasmids were used at a final concentration of 1.5 mg/mL and the mPFC was targeted for transfection. Pregnant dams were returned to the same housing conditions after recovery from surgery, and after litters were born, transfected rats were used for experiments at days P18-P24.
The mouse model used for Pitt-Hopkins syndrome (Sweatt, 2013) was heterozygous for a deletion of the DNA-binding domain of the Transcription Factor 4 (B6;129-TCF4tm1Zhu/J; stock number 013598, Jackson Laboratory, RRID: IMSR_JAX:013598) (Zhuang et al., 1996) . Control mouse experiments were conducted with wild-type littermates. Mice were maintained by SoBran on a 12 hr light cycle and fed ad libitum.
Electrophysiology
For all experiments, as previously described (Maher and LoTurco, 2012b) , artificial cerebrospinal fluid (ACSF) was oxygenated (95% 0 2 and 5% CO 2 ) and contained 125 mM NaCl, 25 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 3 mM KCl, 25 mM dextrose, 1 mM MgCl 2 , and 2 mM CaCl 2 (pH 7.3). Patch pipettes were fabricated from borosilicate glass (N51A, King Precision Glass) to a resistance of 2-5 MU. For current-and voltage-clamp measurements, pipettes were filled with 125 mM potassium gluconate, 10 mM HEPES, 4 mM Mg-ATP, 0.3 mM Na-GTP, 0.1 mM EGTA, and 10 mM phosophocreatine, adjusted to pH 7.3 with KOH. For generation of I/O curves, all cells were recorded from their inherent resting membrane potential. For AHP current experiments, synaptic currents were blocked with DL-2-amino-5-phosphopentanoic acid (D,L-AP5, 100 mM, Ascent Scientific), 2,3, dioxo-6-nitro-1,2,3,4, tetrahydrobenzo-quinoxaline-7-sulfonamide (NBQX, 10 mM), and SR-95531 (Gabazine, 5 mM, Ascent Scientific). Calcium-activated currents were blocked with Tetraethylammonium chloride (TEA, 1 mM, Abcam) and apamin (100 nM, Abcam).
Current signals were recorded with either a Multiclamp 700A (Molecular Devices) or an Axopatch 200B amplifier (Molecular Devices) and were filtered at 2 kHz using a built in Bessel filter and digitized at 10 kHz. Voltage signals were filtered and 2 kHz and digitized at 10 kHz. Data were acquired using Axograph on a Dell PC. Data acquisition was terminated when series resistance was >15 MU. For voltage-clamp recordings, pyramidal cells were held at À60 mV. No holding current was used for current-clamp recordings.
shRNA Constructs Hairpin sequences were designed to target the 3 0 UTR of Tcf4 (shTCF4_2; 5 0 -GTTTCAGCATTCCCAATTA-3 0 ; nucleotide position 65507957 to 65507975; accession number GenBank: CM000089.5) and the open reading frame of Tcf4 (shTCF4; 5 0 -AGAAACTAGACGACGACAA-3 0 ; nucleotide position 65503088-65503106; accession number GenBank: CM000089.5). The control hairpin (shCon) was designed to target DsRed (5 0 -AGTTCCAGTACGGCTC CAA-3 0 ) (Duan et al., 2007) . Sense and anti-sense oligonucleotides were designed, annealed, and cloned into the BbsI and XbaI sites of the mU6pro vector, where expression of short hairpin RNA was under the control of mouse U6 promoter.
CRISPR-Cas9
sgRNA was designed for spCas9 PAM recognition elements in a common exon of Tcf4 (guide G 5 0 -ATAACGCCCGTGAGCGCCTG-3 0 ; nucleotide position 64692509 to 64692528), and off-target effects were minimized by using the online CRISPR-Cas9 design tool (http://crispr.mit.edu/) with none predicted within any genes. A ''G'' was added to the sgRNA sequence for compatibility with U6 promoter. The annealed oligonucleotide was cloned into the BbsI site of the PX458 vector (Ran et al., 2013 ) (Addgene 48138) and sequenced for confirmation. The mis-match sensitive SURVEYOR nuclease assay was performed on genomic DNA extracted from neuroblastoma cells following manufacturer protocol (Transgenesis) 48 hr post-transfection to confirm functional CRISPR-Cas9-mediated editing. pCAG-GFP plasmid was also used to verify transfection efficiency. To determine CRISPR-Cas9 generated mutations, we subjected purified DNA from transfected rat neuroblastoma cells to PCR amplification and TA cloning. Primers were designed using Primer3 software (http://bioinfo.ut.ee/primer3-0.4.0/). Individual plasmid clones were purified and sequenced. In all experiments, a PX458 vector with no sgRNA guide (crEmpty) was used as a control.
iTRAP TRAP was performed as previously described (Heiman et al., 2014 ) with the following additions described below. C2-EGFP-L10a was cloned into the XmaI and NotI sites of the pCAG-GFP plasmid (Addgene 11150), where expression was under the control of the CAG promoter. Replicate tissue samples were prepared from three litters of 7-9 Wistar rats that had been transfected by in utero electroporation in mPFC with L10a-GFP plasmid and either shTCF4 or shCon. P22 rats were deeply anesthetized with isofluorane before transcardial perfusion with ice-cold buffer containing 83 mM NaCl, 2.5 mM KCl, 1 mM NaH 2 PO 4 , 26.2 mM NaHCO 3 , 22 mM glucose, 72 mM sucrose, 0.5 mM CaCl 2 , and 3.3 mM MgCl 2 (oxygenated with 95% O 2 and 5% CO 2 ). Rats were decapitated, and their brains removed and placed into dissection buffer containing cycloheximide. The transfected prefrontal cortex of each brain was dissected and all brains from a replicate litter were pooled into a Teflon-glass homogenizer and homogenized at 900 rpm. Samples were cleared of nuclei and debris by centrifugation and incubated with detergents NP-40 (30 mM) and DHPC (1%) for 5 min before a final 20,000 3 g centrifugation for 15 min. Supernatant from each sample was then incubated for 1 hr at 4 C with protein-G-coated magnetic beads (Invitrogen) conjugated to monoclonal anti-GFP antibodies (19C8 and 19F7, Rockefeller University) . Following conjugation, supernatant was taken from the unbound fraction as an unbound total RNA control sample. Trizol reagent RNA extraction from samples was done following manufacturer protocol (Ambion). Samples were also purified by DNase treatment before concentration with RNeasy min-elute columns (QIAGEN). RNA quantity was measured with an Invitrogen Qubit, and RNA quality was confirmed with an Agilent BioAnalyzer (RIN > 8).
All human subject protocols were approved by the Institutional Review Boards of NIMH/NIH, University of Maryland at Baltimore and the State of 
